Rethinking the Philippines' E-Cigarette Law: Manila Standard Editorial

Feb.07.2024
Rethinking the Philippines' E-Cigarette Law: Manila Standard Editorial
Philippine newspaper Manila Standard calls for a reassessment of the country's e-cigarette law in an editorial.

The large Philippine newspaper Manila Standard recently published an editorial calling for a reassessment of the country's e-cigarette bill.


On July 25, 2022, the Republic Act No. 11900 was enacted in the Philippines with the aim of regulating the importation, sale, packaging, distribution, use, and promotion of "vaporized nicotine and non-nicotine products, as well as new tobacco products such as vape and heated tobacco products." However, in the past two years since its introduction, the law has lowered the age restriction for such products from 21 to 18 years old, lifted the ban on smoking and using heated tobacco products in public places, and allowed advertising and promotion of these products.


The law allows for the online sale of products with nicotine concentrations not exceeding 65 milligrams per milliliter (6.5%), and lowers the legal purchasing age from 21 to 18. This means that more young people will be able to use e-cigarettes as an alternative to smoking (the legal age to purchase cigarettes is 18).


The editorial argues that this law overlooks the fact that tobacco is the highest risk factor for causing deaths and disabilities in both smokers and non-smokers in 2019.


It is estimated that tobacco use was responsible for over 112,112 deaths, accounting for 27% of the total deaths in the Philippines that year.


According to researchers, 96,000 deaths (85%) are caused by smoking, while 22,000 deaths (19%) are caused by secondhand smoke. It is estimated that approximately 8 million people die prematurely every year due to cigarette smoke, which is a complex mixture of chemicals combined with aerosol particles or present in the gas phase. This has been a major health issue for several decades.


The report also noted that the main reasons why students use e-cigarettes include easy online access (32%), flavors (22%), and a perception that e-cigarettes are safer than traditional cigarettes (17%).


Editorial: The editorial asserts that e-cigarettes have not been around for a long time, and authorities are still uncertain about the long-term risks associated with their use. While the harm posed by vaping is considerably lesser than smoking, it cannot be deemed entirely harmless. This is where the problem lies. Therefore, the healthiest choice would be to abstain from smoking or vaping altogether.


The editorial also quotes health experts saying, "If someone uses e-cigarettes to quit smoking, their ultimate goal should be to eventually quit using e-cigarettes." The article further mentions that according to research, emerging data suggests a link between e-cigarettes and chronic lung diseases and asthma. Additionally, using both e-cigarettes and traditional cigarettes has also been associated with cardiovascular diseases.


In conclusion, there is not much difference between smoking and using e-cigarettes, as stated in the editorial. People generally believe that smoking is more harmful because the products are burned and smoke is inhaled into the lungs. However, research has shown that the damage caused by heating and inhaling solution vapor into the lungs is very similar to that of smoke. Based on this, the report calls for a reevaluation of the country's e-cigarette legislation.


The Manila Standard newspaper was established on February 11, 1987. It is controlled by the Romualdez political family, specifically the current Speaker of the House of Representatives, Ferdinand Martin Gomez Romualdez.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Juul Sublicense Reshapes Vuse Alto Patent Bill as Court Ends R.J. Reynolds’ 5.25% Royalty Obligation to Altria
Juul Sublicense Reshapes Vuse Alto Patent Bill as Court Ends R.J. Reynolds’ 5.25% Royalty Obligation to Altria
According to Law360 on August 31, 2026, a federal judge in North Carolina ruled that a patent sublicense between R.J. Reynolds Vapor Co. and Juul Labs Inc. relieves Reynolds of its obligation to continue paying royalties to Altria Client Services LLC over Vuse Alto. A jury had previously found that Vuse Alto infringed three Altria patents and awarded approximately $95.2 million in past damages, after which Reynolds was ordered to pay an ongoing royalty equal to 5.25% of positive net sales. The new ruling finds that a valid sublicense can eliminate future infringement, potentially ending what Altria described as hundreds of millions of dollars in future royalties.
Sep.01
Virginia Tobacco Retail Permit Takes Effect October 1, Covering Vapes as More Than 3,000 Businesses Apply in September
Virginia Tobacco Retail Permit Takes Effect October 1, Covering Vapes as More Than 3,000 Businesses Apply in September
Virginia's new retail tobacco permit system took effect October 1, requiring sellers of vapes, nicotine products and related devices and accessories to obtain a Retail Tobacco Permit for each business location. Virginia ABC said more than 3,000 businesses applied in September alone, creating a processing backlog. Qualifying applicants that filed before October 1 may temporarily operate under a Letter of Authorization. The new store-level permit also sits alongside Virginia's existing vape product directory, where sales of unlisted liquid nicotine or nicotine vapor products can trigger civil penalties starting at $5,000.
Regulations
Oct.03
Product | JT to Launch MEVIUS Tropical Option in Japan, Expanding Ploom Tobacco Stick Lineup to 32
Product | JT to Launch MEVIUS Tropical Option in Japan, Expanding Ploom Tobacco Stick Lineup to 32
Japan Tobacco (JT) will launch MEVIUS Tropical Option, a new tobacco stick for Ploom, nationwide in Japan from October 6, 2026. The capsule-format product combines mango-oriented sweetness with menthol cooling, adding a tropical flavor to the MEVIUS Ploom tobacco-stick lineup for the first time. Each pack contains 20 sticks and will launch at JPY 590. The product is compatible with all Ploom devices, and its addition will expand the Ploom tobacco-stick portfolio to 32 variants.
Sep.08
Product | SnowPlus Launches Nicotine-Free DASH in South Korea, Localising an Established Disposable Platform
Product | SnowPlus Launches Nicotine-Free DASH in South Korea, Localising an Established Disposable Platform
SnowPlus has introduced a nicotine-free version of DASH in South Korea, adapting an existing overseas disposable platform for the local market. The Korean version retains the series’ flat duckbill-style mouthpiece, ceramic heating architecture and disposable form factor while reducing nicotine content to 0%. By comparison, the overseas DASH 4000 platform typically features 7.5ml of prefilled e-liquid, up to 4,000 puffs and a 530mAh rechargeable battery, with nicotine-containing variants available in some markets. The product update centers on formulation localisation rather than a new hardware generation.
Aug.31
JTI Invests ₱2.1 Billion to Upgrade Batangas Manufacturing Hub, Adds First Southeast Asia DIET Facility
JTI Invests ₱2.1 Billion to Upgrade Batangas Manufacturing Hub, Adds First Southeast Asia DIET Facility
JTI Asia Manufacturing Corp. has invested ₱2.1 billion, or about $37 million, in its manufacturing site in Malvar, Batangas, Philippines, to expand tobacco-processing capabilities. About ₱1.9 billion is allocated to JTI's first Dry Ice Expanded Tobacco, or DIET, facility in Southeast Asia, while more than ₱177 million has been spent on expanding its Controlled Atmosphere treatment facility. The Batangas plant supplies the Philippine market and exports to 22 overseas markets, making it one of JTI's key manufacturing hubs in Asia.
Sep.24
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
At the 2026 NACS Show in Las Vegas, Philip Morris International (PMI) showcased its ZYN nicotine pouches, IQOS heated tobacco products and U.S. investments. A 2Firsts review of FDA records found that several ZYN products displayed at the booth were not on the agency's marketing authorization list, including certain nicotine strengths and flavors. A PMI booth representative also confirmed that IQOS is currently sold in three U.S. states, while the newer IQOS ILUMA system remains under FDA review.
EXPO
Oct.10